FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2004-2006 May 6, 2004 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Snyder, P. J. Related Article by Rhoden, E. L. PubMed Citation

To the Editor: Rhoden and Morgentaler¹ and Snyder² (Jan. 29 issue) assuage the anxiety of physicians who administer testosterone to older men because the men report andropause, a collection of ill-defined maladies related to male aging. Their position in this regard is very disconcerting.

More than 50 years ago, physicians began treating the "male climacteric" with testosterone.³ Since then, no standardized definition of this condition has been developed, no metric defining a therapeutic effect has been created, no randomized controlled studies have been conducted to support the widespread use of testosterone in men for this condition, and the adverse-event profile . . . [Full Text of this Article]

This article has been cited by other articles:

• Kiayias, J. A., Vlachou, E. D., Bakides, S., Petridou, E., Migdalis, I. N. (2006). Prostatic Cancer, Hypogonadism, and Insulin Resistance: A case report. Diabetes Care 29: 1178-1179 [Full Text]  
• Morgentaler, A. (2004). A 66-Year-Old Man With Sexual Dysfunction. JAMA 291: 2994-3003 [Full Text]